Fiche société
Akebia Therapeutics
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications1liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ADX-097A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G) | Lupus | Phase 2 | À vérifier | United States, Brazil | À vérifier |
| ADX-097A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G) | Lupus | Phase 2 | À vérifier | United States, Brazil | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ADX-097 | Lupus | Phase 2 | NCT06419205 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G | RECRUITING |
Publications
1| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| ADX-097 | C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement. | Molecular therapy : the journal of the American Society of Gene Therapy |